A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 06 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.